LogicBio Therapeutics (LPRO) Downgraded by Zacks Investment Research to Hold

LogicBio Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  LogicBio Therapeutics Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More LogicBio Therapeutics (LPRO) Downgraded by Zacks Investment Research to Hold